Drugs / Desiccated Thyroid Extract
Desiccated Thyroid Extract
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT04124705 | Oct 2019 → Jun 2021 | hypothyroidism | Allergan | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06345339 | Apr 2024 → Sep 2027 expected | hypothyroidism | AbbVie | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07239674 | Nov 2025 → Nov 2027 expected | differentiated thyroid carcinoma | West China Hospital | Not yet recruiting | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT02317926 Comparator | May 2015 → May 2018 | hypothyroidism | Walter Reed National Military Medical Center | Unknown | No outcome recorded |
| — | NCT01739972 Comparator | May 2012 → May 2014 | peripheral hypothyroidism | Walter Reed National Military Medical Center | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Desiccated Thyroid Extract | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02317926 ↗ |
| Known as | Armour Thyroid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04124705 ↗ |
| Known as | DTE | “Desiccated thyroid extract (DTE) is a dry preparation obtained from animal thyroid glands that contains both thyroxine (T4) and triiodothyronine (T3) in an approximately 4:1...” NCT07239674 ↗ |
| Route | Oral | “Administered orally once a day.” NCT04124705 ↗ |